Functional loss of B-cell maturation antigen (BCMA) is a recognised mechanism of relapse after BCMA-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma. Targeting multiple tumour antigens simultaneously with a single CAR has the potential to mitigate antigen escape and prolong disease responses.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile